nmda receptor antagonists Search Results


weak nmda receptor antagonist amantadine gocovritm  (Adamas Pharmaceuticals)
90
Adamas Pharmaceuticals weak nmda receptor antagonist amantadine gocovritm
Weak Nmda Receptor Antagonist Amantadine Gocovritm, supplied by Adamas Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nmda+receptor+antagonists/pm35988699-145-6-11?v=Adamas+Pharmaceuticals
Average 90 stars, based on 1 article reviews
weak nmda receptor antagonist amantadine gocovritm - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
nmda receptor antagonist apv  (HFS LTD)
90
HFS LTD nmda receptor antagonist apv
Nmda Receptor Antagonist Apv, supplied by HFS LTD, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nmda+receptor+antagonists/pmc09877298-150-23-2?v=HFS+LTD
Average 90 stars, based on 1 article reviews
nmda receptor antagonist apv - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
nmda receptor antagonists  (Auspex Pharma)
90
Auspex Pharma nmda receptor antagonists
(Top) Schematic representation of the linear amino acid sequence that encodes each subunit. ATD is the amino terminal domain. The S1 and S2 domains fold together to form the ligand binding domain (LBD). M1 through M4 form the transmembrane domain (TMD); M1, M3 and M4 are transmembrane helices and M2 is a re-entrant loop. (Left) Ribbon diagram of homology modeled GluN1-GluN2A <t>NMDA</t> receptor (generated using PyMOL Molecular Graphics System, Version 1.2r3pre, Schrödinger, LLC). The GluN1 subunits are depicted in yellow and the GluN2A subunits are in green. Known modulatory regions are circled and labeled. (Right) Single subunits of GluN1-GluN2 receptor describing the domain architecture. The S1 region of the LBD is in blue and the S2 region is in red.
Nmda Receptor Antagonists, supplied by Auspex Pharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nmda+receptor+antagonists/pmc03677696-220-13-2?v=Auspex+Pharma
Average 90 stars, based on 1 article reviews
nmda receptor antagonists - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
dual p2x7 – nmda receptors antagonists  (MultiTarget Pharmaceuticals)
90
MultiTarget Pharmaceuticals dual p2x7 – nmda receptors antagonists
(Top) Schematic representation of the linear amino acid sequence that encodes each subunit. ATD is the amino terminal domain. The S1 and S2 domains fold together to form the ligand binding domain (LBD). M1 through M4 form the transmembrane domain (TMD); M1, M3 and M4 are transmembrane helices and M2 is a re-entrant loop. (Left) Ribbon diagram of homology modeled GluN1-GluN2A <t>NMDA</t> receptor (generated using PyMOL Molecular Graphics System, Version 1.2r3pre, Schrödinger, LLC). The GluN1 subunits are depicted in yellow and the GluN2A subunits are in green. Known modulatory regions are circled and labeled. (Right) Single subunits of GluN1-GluN2 receptor describing the domain architecture. The S1 region of the LBD is in blue and the S2 region is in red.
Dual P2x7 – Nmda Receptors Antagonists, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nmda+receptor+antagonists/pmc06017257__molecules___23___00230___s001-0-9-9?v=MultiTarget+Pharmaceuticals
Average 90 stars, based on 1 article reviews
dual p2x7 – nmda receptors antagonists - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
glutamatergic n-methyl-d-aspartic acid (nmda) receptor antagonist ketamine  (Neurolixis)
90
Neurolixis glutamatergic n-methyl-d-aspartic acid (nmda) receptor antagonist ketamine
(Top) Schematic representation of the linear amino acid sequence that encodes each subunit. ATD is the amino terminal domain. The S1 and S2 domains fold together to form the ligand binding domain (LBD). M1 through M4 form the transmembrane domain (TMD); M1, M3 and M4 are transmembrane helices and M2 is a re-entrant loop. (Left) Ribbon diagram of homology modeled GluN1-GluN2A <t>NMDA</t> receptor (generated using PyMOL Molecular Graphics System, Version 1.2r3pre, Schrödinger, LLC). The GluN1 subunits are depicted in yellow and the GluN2A subunits are in green. Known modulatory regions are circled and labeled. (Right) Single subunits of GluN1-GluN2 receptor describing the domain architecture. The S1 region of the LBD is in blue and the S2 region is in red.
Glutamatergic N Methyl D Aspartic Acid (Nmda) Receptor Antagonist Ketamine, supplied by Neurolixis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nmda+receptor+antagonists/pm37310446-15-2-40?v=Neurolixis
Average 90 stars, based on 1 article reviews
glutamatergic n-methyl-d-aspartic acid (nmda) receptor antagonist ketamine - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
nmda receptor antagonist apv  (Cayman Chemical)
90
Cayman Chemical nmda receptor antagonist apv
(Top) Schematic representation of the linear amino acid sequence that encodes each subunit. ATD is the amino terminal domain. The S1 and S2 domains fold together to form the ligand binding domain (LBD). M1 through M4 form the transmembrane domain (TMD); M1, M3 and M4 are transmembrane helices and M2 is a re-entrant loop. (Left) Ribbon diagram of homology modeled GluN1-GluN2A <t>NMDA</t> receptor (generated using PyMOL Molecular Graphics System, Version 1.2r3pre, Schrödinger, LLC). The GluN1 subunits are depicted in yellow and the GluN2A subunits are in green. Known modulatory regions are circled and labeled. (Right) Single subunits of GluN1-GluN2 receptor describing the domain architecture. The S1 region of the LBD is in blue and the S2 region is in red.
Nmda Receptor Antagonist Apv, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nmda+receptor+antagonists/pmc07779207-101-4-5?v=Cayman+Chemical
Average 90 stars, based on 1 article reviews
nmda receptor antagonist apv - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
n-methyl-d-aspartate receptor (nmda) antagonists  (Pain Therapeutics)
90
Pain Therapeutics n-methyl-d-aspartate receptor (nmda) antagonists
(Top) Schematic representation of the linear amino acid sequence that encodes each subunit. ATD is the amino terminal domain. The S1 and S2 domains fold together to form the ligand binding domain (LBD). M1 through M4 form the transmembrane domain (TMD); M1, M3 and M4 are transmembrane helices and M2 is a re-entrant loop. (Left) Ribbon diagram of homology modeled GluN1-GluN2A <t>NMDA</t> receptor (generated using PyMOL Molecular Graphics System, Version 1.2r3pre, Schrödinger, LLC). The GluN1 subunits are depicted in yellow and the GluN2A subunits are in green. Known modulatory regions are circled and labeled. (Right) Single subunits of GluN1-GluN2 receptor describing the domain architecture. The S1 region of the LBD is in blue and the S2 region is in red.
N Methyl D Aspartate Receptor (Nmda) Antagonists, supplied by Pain Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nmda+receptor+antagonists/pmc04594737-493-0-6?v=Pain+Therapeutics
Average 90 stars, based on 1 article reviews
n-methyl-d-aspartate receptor (nmda) antagonists - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
mk-801  (Florey Institute of Neuroscience and Mental Health)
90
Florey Institute of Neuroscience and Mental Health mk-801
(Top) Schematic representation of the linear amino acid sequence that encodes each subunit. ATD is the amino terminal domain. The S1 and S2 domains fold together to form the ligand binding domain (LBD). M1 through M4 form the transmembrane domain (TMD); M1, M3 and M4 are transmembrane helices and M2 is a re-entrant loop. (Left) Ribbon diagram of homology modeled GluN1-GluN2A <t>NMDA</t> receptor (generated using PyMOL Molecular Graphics System, Version 1.2r3pre, Schrödinger, LLC). The GluN1 subunits are depicted in yellow and the GluN2A subunits are in green. Known modulatory regions are circled and labeled. (Right) Single subunits of GluN1-GluN2 receptor describing the domain architecture. The S1 region of the LBD is in blue and the S2 region is in red.
Mk 801, supplied by Florey Institute of Neuroscience and Mental Health, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nmda+receptor+antagonists/10__1111_slash_j__1471___4159__2009__06239__x-1520-0-21?v=Florey+Institute+of+Neuroscience+and+Mental+Health
Average 90 stars, based on 1 article reviews
mk-801 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
nmda receptor antagonists  (NeuroRx Research)
90
NeuroRx Research nmda receptor antagonists
(Top) Schematic representation of the linear amino acid sequence that encodes each subunit. ATD is the amino terminal domain. The S1 and S2 domains fold together to form the ligand binding domain (LBD). M1 through M4 form the transmembrane domain (TMD); M1, M3 and M4 are transmembrane helices and M2 is a re-entrant loop. (Left) Ribbon diagram of homology modeled GluN1-GluN2A <t>NMDA</t> receptor (generated using PyMOL Molecular Graphics System, Version 1.2r3pre, Schrödinger, LLC). The GluN1 subunits are depicted in yellow and the GluN2A subunits are in green. Known modulatory regions are circled and labeled. (Right) Single subunits of GluN1-GluN2 receptor describing the domain architecture. The S1 region of the LBD is in blue and the S2 region is in red.
Nmda Receptor Antagonists, supplied by NeuroRx Research, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nmda+receptor+antagonists/us07994218-689-0-11?v=NeuroRx+Research
Average 90 stars, based on 1 article reviews
nmda receptor antagonists - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
nmda receptor antagonist  (Cerebral Therapeutics)
90
Cerebral Therapeutics nmda receptor antagonist
Schematic diagram of some of the signaling pathways involved in death of putamen medium spiny neurons in the piglet hypoxia + asphyxia model. Dashed line = inhibitory effect; D1R: <t>dopamine</t> <t>receptor-1;</t> A2AR: adenosine receptor 2A; NKA: Na,K-ATPase; DARPP-32: dopamine and adenylate cyclase regulated phosphoprotein; PP1: protein phosphatase 1; ASIC1a: acid-sensitive ion channel 1a; σ1R: σ-1 receptor; GluNR1: <t>NMDA</t> receptor subunit 1; GluNR2: NMDA receptor subunit 2; NO: nitric oxide; nNOS: neuronal NO synthase; O2–: superoxide anion; ONOO–: peroxynitrite; PSD95: postsynaptic density-95; AA: arachidonic acid.
Nmda Receptor Antagonist, supplied by Cerebral Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nmda+receptor+antagonists/pmc06282216-164-40-13?v=Cerebral+Therapeutics
Average 90 stars, based on 1 article reviews
nmda receptor antagonist - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
nmda receptor antagonist effects of the stereoisomers of beta-cyclazocine  (Millar Inc)
90
Millar Inc nmda receptor antagonist effects of the stereoisomers of beta-cyclazocine
Schematic diagram of some of the signaling pathways involved in death of putamen medium spiny neurons in the piglet hypoxia + asphyxia model. Dashed line = inhibitory effect; D1R: <t>dopamine</t> <t>receptor-1;</t> A2AR: adenosine receptor 2A; NKA: Na,K-ATPase; DARPP-32: dopamine and adenylate cyclase regulated phosphoprotein; PP1: protein phosphatase 1; ASIC1a: acid-sensitive ion channel 1a; σ1R: σ-1 receptor; GluNR1: <t>NMDA</t> receptor subunit 1; GluNR2: NMDA receptor subunit 2; NO: nitric oxide; nNOS: neuronal NO synthase; O2–: superoxide anion; ONOO–: peroxynitrite; PSD95: postsynaptic density-95; AA: arachidonic acid.
Nmda Receptor Antagonist Effects Of The Stereoisomers Of Beta Cyclazocine, supplied by Millar Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nmda+receptor+antagonists/pmc04556466-555-19-5?v=Millar+Inc
Average 90 stars, based on 1 article reviews
nmda receptor antagonist effects of the stereoisomers of beta-cyclazocine - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
nmda receptor antagonists  (Neurobiological Technologies Inc)
90
Neurobiological Technologies Inc nmda receptor antagonists
Schematic diagram of some of the signaling pathways involved in death of putamen medium spiny neurons in the piglet hypoxia + asphyxia model. Dashed line = inhibitory effect; D1R: <t>dopamine</t> <t>receptor-1;</t> A2AR: adenosine receptor 2A; NKA: Na,K-ATPase; DARPP-32: dopamine and adenylate cyclase regulated phosphoprotein; PP1: protein phosphatase 1; ASIC1a: acid-sensitive ion channel 1a; σ1R: σ-1 receptor; GluNR1: <t>NMDA</t> receptor subunit 1; GluNR2: NMDA receptor subunit 2; NO: nitric oxide; nNOS: neuronal NO synthase; O2–: superoxide anion; ONOO–: peroxynitrite; PSD95: postsynaptic density-95; AA: arachidonic acid.
Nmda Receptor Antagonists, supplied by Neurobiological Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nmda+receptor+antagonists/pm10754324-39-26-12?v=Neurobiological+Technologies+Inc
Average 90 stars, based on 1 article reviews
nmda receptor antagonists - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

Image Search Results


(Top) Schematic representation of the linear amino acid sequence that encodes each subunit. ATD is the amino terminal domain. The S1 and S2 domains fold together to form the ligand binding domain (LBD). M1 through M4 form the transmembrane domain (TMD); M1, M3 and M4 are transmembrane helices and M2 is a re-entrant loop. (Left) Ribbon diagram of homology modeled GluN1-GluN2A NMDA receptor (generated using PyMOL Molecular Graphics System, Version 1.2r3pre, Schrödinger, LLC). The GluN1 subunits are depicted in yellow and the GluN2A subunits are in green. Known modulatory regions are circled and labeled. (Right) Single subunits of GluN1-GluN2 receptor describing the domain architecture. The S1 region of the LBD is in blue and the S2 region is in red.

Journal: Expert opinion on therapeutic patents

Article Title: Novel NMDA Receptor Modulators: An Update

doi: 10.1517/13543776.2012.728587

Figure Lengend Snippet: (Top) Schematic representation of the linear amino acid sequence that encodes each subunit. ATD is the amino terminal domain. The S1 and S2 domains fold together to form the ligand binding domain (LBD). M1 through M4 form the transmembrane domain (TMD); M1, M3 and M4 are transmembrane helices and M2 is a re-entrant loop. (Left) Ribbon diagram of homology modeled GluN1-GluN2A NMDA receptor (generated using PyMOL Molecular Graphics System, Version 1.2r3pre, Schrödinger, LLC). The GluN1 subunits are depicted in yellow and the GluN2A subunits are in green. Known modulatory regions are circled and labeled. (Right) Single subunits of GluN1-GluN2 receptor describing the domain architecture. The S1 region of the LBD is in blue and the S2 region is in red.

Article Snippet: One company, Auspex Pharmaceuticals, has focused on enhancing the pharmacokinetic properties of known NMDA receptor antagonists by incorporating deuterium in place of hydrogen.

Techniques: Sequencing, Ligand Binding Assay, Generated, Labeling

Potentiation of NMDA-Evoked Current

Journal: Expert opinion on therapeutic patents

Article Title: Novel NMDA Receptor Modulators: An Update

doi: 10.1517/13543776.2012.728587

Figure Lengend Snippet: Potentiation of NMDA-Evoked Current

Article Snippet: One company, Auspex Pharmaceuticals, has focused on enhancing the pharmacokinetic properties of known NMDA receptor antagonists by incorporating deuterium in place of hydrogen.

Techniques: Concentration Assay

Schematic diagram of some of the signaling pathways involved in death of putamen medium spiny neurons in the piglet hypoxia + asphyxia model. Dashed line = inhibitory effect; D1R: dopamine receptor-1; A2AR: adenosine receptor 2A; NKA: Na,K-ATPase; DARPP-32: dopamine and adenylate cyclase regulated phosphoprotein; PP1: protein phosphatase 1; ASIC1a: acid-sensitive ion channel 1a; σ1R: σ-1 receptor; GluNR1: NMDA receptor subunit 1; GluNR2: NMDA receptor subunit 2; NO: nitric oxide; nNOS: neuronal NO synthase; O2–: superoxide anion; ONOO–: peroxynitrite; PSD95: postsynaptic density-95; AA: arachidonic acid.

Journal: Journal of Cerebral Blood Flow & Metabolism

Article Title: Perinatal hypoxic-ischemic brain injury in large animal models: Relevance to human neonatal encephalopathy

doi: 10.1177/0271678X18797328

Figure Lengend Snippet: Schematic diagram of some of the signaling pathways involved in death of putamen medium spiny neurons in the piglet hypoxia + asphyxia model. Dashed line = inhibitory effect; D1R: dopamine receptor-1; A2AR: adenosine receptor 2A; NKA: Na,K-ATPase; DARPP-32: dopamine and adenylate cyclase regulated phosphoprotein; PP1: protein phosphatase 1; ASIC1a: acid-sensitive ion channel 1a; σ1R: σ-1 receptor; GluNR1: NMDA receptor subunit 1; GluNR2: NMDA receptor subunit 2; NO: nitric oxide; nNOS: neuronal NO synthase; O2–: superoxide anion; ONOO–: peroxynitrite; PSD95: postsynaptic density-95; AA: arachidonic acid.

Article Snippet: 81 The cerebral ischemia model has the advantage of being able to investigate cerebral therapeutics without the variability encountered from impaired cardiac function in the umbilical cord occlusion model. For example, benefits have been demonstrated with delayed administration of an NMDA receptor antagonist, 82 insulin-like growth factor-1, 83 and a connexin hemichannel peptide blocker.

Techniques: Protein-Protein interactions